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Abstract
Autism is a severe neurodevelopmental disorder that is characterized by impaired language, communication, and social
skills. In regressive autism, affected children first show signs of normal social and language development but eventually lose
these skills and develop autistic behavior. Protein kinases are essential in G-protein-coupled, receptor-mediated signal
transduction and are involved in neuronal functions, gene expression, memory, and cell differentiation. We studied the
activity and expression of protein kinase A (PKA), a cyclic AMP–dependent protein kinase, in postmortem brain tissue
samples from the frontal, temporal, parietal, and occipital cortices, and the cerebellum of individuals with regressive autism;
autistic subjects without a clinical history of regression; and age-matched developmentally normal control subjects. The
activity of PKA and the expression of PKA (C-a), a catalytic subunit of PKA, were significantly decreased in the frontal cortex
of individuals with regressive autism compared to control subjects and individuals with non-regressive autism. Such
changes were not observed in the cerebellum, or the cortices from the temporal, parietal, and occipital regions of the brain
in subjects with regressive autism. In addition, there was no significant difference in PKA activity or expression of PKA (C-a)
between non-regressive autism and control groups. These results suggest that regression in autism may be associated, in
part, with decreased PKA-mediated phosphorylation of proteins and abnormalities in cellular signaling.
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Introduction
Autism spectrum disorders (ASDs) are neurodevelopmental
disorders characterized by impairment in social interactions and
verbal/non-verbal communication skills, and restricted, repetitive
and stereotyped patterns of behavior [1]. According to a recent
report from the Centers for Disease Control and Prevention, the
prevalence of ASDs is 1 in 110 for children 8 years of age [2].
The symptoms of ASDs are typically present before the age of 3
years, and are often accompanied by abnormalities in cognitive
functioning, learning, attention, and sensory processing. While
the causes of ASDs remain elusive, ASDs are considered to be
heterogeneous and multifactorial disorders that are influenced by
both genetic and environmental factors. The onset of autism is
gradual in many children. However, in regressive autism,
children first show signs of normal social and language
development but lose these developmental skills at 15–24 months
and develop autistic behavior [3]. The reported incidence of
regressive autism varies in different studies from 15% to 62% of
cases [4–7]. In a few cases, regression may significantly affect
language, with lesser impact in other domains such as social
interaction or imaginative play [4,8]. On the other hand, some
children may regress especially in social functions and not in
language [9].
Protein kinases are known to play important roles in cellular
signaling pathways and are involved in brain development [10–
13]. Protein kinase A (PKA) is a cyclic adenosine monophosphate
(cAMP)–dependent protein kinase that is involved in cognitive
functions and memory formation [14–18]. PKA consists of
regulatory (R) and catalytic (C) subunits. Three genes encode for
catalytic units (Ca,C b, and Cc), and four other genes encode for
regulatory units (RIa,R I b, RIIa, and RIIb) of PKA. PKA remains
catalytically inactive when the levels of cAMP are low. The
concentration of cAMP rises upon activation of adenylate cyclase
by G protein-coupled receptors, and/or inhibition of cyclic
nucleotide phosphodiesterase (PDE) enzyme. Under these condi-
tions, cAMP binds to two binding sites on the regulatory subunits
of PKA, which results in the release of the catalytic subunits. These
free catalytic units of PKA can then phosphorylate proteins by
transferring a phosphate group from ATP. Several studies have
implicated the role of PKA in neuropsychiatric disorders such as
schizophrenia, bipolar affective disorder, obsessive compulsive
disorder, and panic disorders [19–22]. To date, no studies of PKA
have been done in autism.
The intracellular levels of cAMP are controlled by PDE, which
degrades the phosphodiester bond in cAMP. PDE regulates the
localization, duration, and amplitude of cAMP signaling within
subcellular domains. Multiple forms of PDEs have been identified
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23751on the basis of substrate specificity. PDE4, 7, and 8 act on cAMP;
PDE5, 6, and 9 act on cyclic guanosine monophosphate (cGMP);
whereas PDE1, 2, 3, 10, and 11 act on both cAMP and cGMP.
Recent evidence has suggested altered levels of PDE4 in the brains
of individuals with autism [23].
Because the levels of PDE4 are altered in autism, and PKA is
involved in neuropsychiatric disorders, it was of interest to
compare the activity and protein levels of PKA in different brain
regions in autism (regressive and non-regressive) and age-matched
control subjects. Our study suggests that PKA activity and
expression are decreased in the frontal cortex of individuals with
regressive autism as compared with control subjects. Such changes
were not observed in individuals with non-regressive autism.
Materials and Methods
Autism and Control Subjects
Samples of postmortem frozen brain regions, i.e., the cerebel-
lum, and the cortices from the frontal, temporal, parietal, and
occipital lobes from autistic (N=7–10 for different brain regions)
and age-matched, typically developed, control subjects (N=9–10)
were obtained from the National Institute of Child Health and
Human Development (NICHD) Brain and Tissue Bank for
Developmental Disorders at the University of Maryland, Balti-
more, MD. The age (mean 6 S.E.) for autistic subjects was
12.663.2 years, and for control subjects, 12.463.3 years. All brain
samples were stored at 270uC.
The case history and clinical characteristics for the autism and
control subjects are summarized in Table 1. Donors with autism
had met the diagnostic criteria of the Diagnostic and Statistical
Manual-IV for autism. The Autism Diagnostic Interview-Revised
(ADI-R) test was performed for the donors UMB #s 4671, 4849,
1174, 797, 1182, 4899, and 1638 (Table 2). Each donor’s
impairments in social interaction, qualitative abnormalities in
communication, and restricted, repetitive and stereotyped patterns
of behavior are consistent with the diagnosis of autism, according
to the results of the ADI-R diagnostic algorithm. All donors with
autism exceeded the cut-off score in these parameters. The
diagnosis of autism was assigned to donor UMB # 1349 after
extensive evaluation of behavioral tests, including the Autism
Diagnostic Observation Schedule (ADOS), Vineland Adaptive
Behavioral Scale (VABS), and Bayley Scales for Infant Develop-
ment-II (BSID-II). In addition to the ADI-R, UMB # 4849 was
also evaluated by the BSID-II and Childhood Autism Rating Scale
(CARS), which indicated moderate to severe autism, and autism in
UMB # 4671 was also verified by the VABS and BSID-II. Table 3
shows scores for the VABS test, which assesses adaptive behavior
in four domains: communication, daily living skills, socialization,
and motor skills.
In this study, the subjects with autism were divided into two
subgroups: regressive autism and non-regressive autism, depend-
ing on the pattern of onset of symptoms for autism. Regressive
autism is a type of autism in which early development is normal,
followed by a loss of previously acquired skills. Language is the
most common area that regresses; this regression can be
accompanied by more global regression involving loss of social
skills and social interest. On the other hand, in non-regressive
autism, the child never gains normal language and social skills, and
initial symptoms are delayed speech development, and/or delay in
development of social skills and in nonverbal communication.
These children do not demonstrate regression in terms of loss of
language or social skills.
Ethics statement. This study was approved by the
Institutional Review Board (IRB) of the New York State
Institute for Basic Research in Developmental Disabilities. The
IRB reviewed this study in accordance with New York State
Regulations and the HHS Office for Human Research
Protections, including the ‘‘Human Subject Decision Chart 1,’’
and found that the research does not involve human subjects because ‘‘the
research does not involve intervention or interaction with the
individuals’’, nor ‘‘is the information individually identifiable’’.
The subjects cannot be identified, directly or through identifiers
linked to the system, and the consent is not required.
Preparation of Brain Homogenates
The tissue samples were homogenized (10% w/v) in cold buffer
containing 50 mM Tris-HCl (pH 7.4), 8.5% sucrose, 2 mM
EDTA, 10 mM b-mercaptoethanol, and protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO) at 4uC. For extraction
of protein kinases, the homogenates were mixed with an equal
volume of extraction buffer containing 40 mM Tris-HCl (pH 7.4),
300 mM NaCl, 2 mM EDTA, 2 mM EGTA, 2% Triton, 5 mM
sodium pyrophosphate, 2 mM b-glycerophosphate, 2 mM
Na3VO4, 100 mM NaF, and 2 mg/ml leupeptin. The samples
were allowed to stand on ice for 10 min, and then centrifuged at
135,000 g for 20 min at 4uC. The supernatants were collected,
and the concentrations of total proteins in the supernatants were
measured by the biocinchoninic acid protein assay kit (Thermo
Scientific, Rockford, IL).
Assay for PKA Activity
PKA activity was measured using the solid phase enzyme-linked
immunosorbent assay (ELISA) kit from Enzo Life Sciences
International, Inc. (Plymouth Meeting, PA). In this assay, the
substrate of PKA was pre-coated on the wells of a microplate. The
microplate wells were soaked with 50 ml of kinase assay dilution
buffer for 10 min. The buffer was then carefully aspirated from
each well, and the brain samples were added to the appropriate
wells. The kinase reaction was initiated by adding 10 ml ATP, and
was carried out for 90 min at 30uC. It was terminated by emptying
the contents of each well. A phosphosubstrate–specific antibody
was added to the wells except in blank, and incubated for 60 min
at room temperature, followed by washing 4 times with wash
buffer. The peroxidase-conjugated secondary antibody was then
added except in blank, and incubation was done for 60 min at
room temperature. The wells were again washed 4 times with
wash buffer. The color was developed with tetramethylbenzidine
substrate, and it was proportional to the phosphotransferase
activity of PKA. The reaction was stopped with acid-stop solution,
and the absorbance was measured at 450 nm in a microplate
reader. The absorbance was divided by the concentration of total
protein (mg) in each sample, and the data are represented as
relative PKA activity.
Western Blot Analysis
Total protein (15 mg) from brain homogenates of subjects with
regressive- and non-regressive autism or control subjects was
separated using a 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and then transferred to a nitrocellulose mem-
brane. The membrane was blocked with Tris-buffered saline
containing 5% fat-free dried milk for 2 h at room temperature,
and further incubated overnight at 4uC with polyclonal antibody
against C-subunit (isoform a) of PKA (Cell Signaling Technology
Inc., Danvers, MA). The membrane was then washed 3 times with
TBS-0.05% Tween 20, and incubated with horseradish peroxi-
dase-conjugated secondary antibody for 2 h at room temperature.
The membrane was washed again, and the immunoreactive
protein was visualized using enhanced chemiluminescent reagent.
Protein Kinase A in Regressive Autism
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23751Because PKA (C-a) and b-actin have similar molecular weights
(42 KDa), polyclonal antibody against PKA (C-a) was stripped
from nitrocellulose membrane, and the membrane was re-probed
with monoclonal antibody against b-actin (loading control). The
densities of all protein bands were measured by NIH Image J
software, and the density of PKA (C-a) band was normalized with
the density of b-actin for each sample.
Statistical Analysis
Initially, autistic and control cases were collected as age-
matched pairs. As data for both members of a pair were not
available in all cases, and data were approximately normally
distributed, unpaired two-tailed t-tests were employed to make
comparisons of PKA activity in various brain regions, and of
overall PKA density between autistic vs. control cases. Compar-
isons among controls and autistic cases showing or not showing
clinical signs of regression in function were made using one-way
analysis of variance (ANOVA). To guard against type I error, a
Bonferroni adjustment for multiple comparisons was made to the
t-tests of multiple brain regions, and for the pairwise post-hoc t-tests
comparing each pair of the three groups that were compared in
the overall ANOVA. For purposes of this adjustment, tests of
different hypotheses, i.e., of activity levels and of protein contents
of PKA, were not considered to be multiple comparisons.
Results
PKA Activity in Different Brain Regions of Individuals with
Autism and Age-Matched Control Subjects: Relationship
with Regression in Autism
The activity of PKA was measur e di nt h eb r a i nh o m o g e n a t e s
from the frontal, temporal, occipital, and parietal cortices, and
the cerebellum in autistic and control subjects (Fig. 1). When all
autism cases (regressive and non-regressive) were compared with
the age-matched control group, no significant difference was
found in PKA activity in any of these brain regions, although
PKA activity in the frontal cortex was found to be reduced by
34.7% in the autism vs. control group. When the autism group
was divided into two sub-groups (regressive and non-regressive),
depending on whether there was a clinical history of regression
or not, unadjusted two-tailed t-test showed a significant decrease
in PKA activity in the frontal cortex of individuals with
regressive autism as compared to the developmentally normal
control group (p=0.0278) and the non-regressive autism group
Table 2. Autism Diagnostic Interview-Revised test scores in donors of brain tissue samples.
Autism Diagnostic Interview-Revised (ADI-R)
a
Diagnostic Algorithm
Cutoff score for
autism UMB 4671 UMB 4849 UMB 1174 UMB 797 UMB 4899 UMB 1638
Impairments in reciprocal social
interaction (Scores:0–30)
10 26 22 22 24 22 21
Abnormalities in communication:
Verbal (Scores:0–26) 8 - 18 - 20 - -
Non-verbal (Scores: 0–14) 7 13 N/A 11 13 14 11
Restricted, repeated and stereotyped
behavior (Scores: 0–12)
3 386687
Abnormalities of development evident
at or before 36 months
15 3 5 - 4 5
a: Higher score represents greater impairment.
UMB 1182: ADI-R was conducted but the scores are not available. The donor met the criteria for a diagnosis of autism.
doi:10.1371/journal.pone.0023751.t002
Table 3. Vineland Adaptive Behavioral Scales diagnostic test for autism in donors of brain tissue samples.
Vineland Adaptive Behavioral Scales (VABS)
a
UMB 1349 UMB 4671 UMB 1174
At age: 25 months At age: 33 months At age: 39 months At age: 6.4 y
Domain (Scores:20–160)
Standard
Score
Age equivalent
performance
Standard
Score
Age equivalent
performance
Standard
Score
Age equivalent
performance
Standard
score
Communication 57 9 months 69 18 months 52 10 months 41
Daily living skills 65 16 months 62 16 months 54 14 months 22
Socialization 60 9 months 71 17 months 51 4 months 52
Motor skills - - - - 65 24 months -
Composite - - - - 51 13 months 35
a: Higher score represents better function.
According to the medical histories for UMB-4231 and UMB-5027, the donors had psychological evaluation, and met the criteria for a diagnosis of autism. Detailed
information is not available.
doi:10.1371/journal.pone.0023751.t003
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after application of the adjustment for multiple comparisons.
The mean 6 S.E. of PKA activity in the frontal cortex was:
2.4860.57 in autism (regressive+non-regressive), 1.6060.31 in
regressive autism, 3.9460.99 in non-regressive autism, and
3.8060.65 in control groups. The alteration in PKA activity was
specific to the frontal cortex in regressive autism because it was
not observed in other regions of the brain, i.e., the cerebellum
and the temporal, parietal, and occipital cortices, suggesting
that the changes observed in PKA activity were brain region–
specific in regressive autism. PKA activity was also similar in all
of the brain regions between non-regressive autism and control
groups.
There was no significant difference in postmortem interval
(PMI) between the autistic and control groups, or between the
regressive autism and non-regressive autism groups. The mean 6
S.E. of PMI was: 22.064.2 in the autism groups (regressive+non-
regressive, n=10), 16.161.22 in the control group (n=10),
28.467.2 in regressive autism (n=5), and 15.662.6 in the non-
regressive autism group (n=5). We also studied whether there was
an inverse correlation between PMI and PKA activity. Correlation
analysis between PMI and PKA activity for all autistic and control
subjects did not reveal any such association (data not shown).
Furthermore, the cerebellum and the temporal, parietal, and
occipital cortices were not affected in subjects with regressive
autism in comparison with control subjects, while the frontal
cortex was affected in these individuals. These results suggest that
PMI was not a contributing factor to the observed alteration in
PKA activity in the frontal cortex of individuals with regressive
autism. There was also no significant difference in age (mean 6
S.E.) between the regressive autism (11.662.7 years, n=5) and
non-regressive autism groups (13.766.1 years, n=5).
Figure 1. PKA activity in different brain regions from regressive autism, non-regressive autism, and age-matched control subjects.
The autism group comprises combined regressive and non-regressive autism sub-groups. Brain homogenates were prepared, and activity of PKA was
measured as described in Materials and Methods. Data represent mean 6 S.E.
doi:10.1371/journal.pone.0023751.g001
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Because a decrease in PKA activity was observed in the frontal
cortex of subjects with regressive autism as compared to control
subjects and subjects with non-regressive autism, we analyzed
whether the decreased activity of PKA is related to the reduced
protein contents of PKA. The protein contents of the catalytic Ca
unit of PKA were analyzed in the frontal cortex of individuals with
autism (regressive and non-regressive) and age-matched controls by
Western blotting (Fig. 2 A). The relative densities of the protein
contents of PKA (C-a) normalized with b-actin are shown in Fig. 2
B. A one-way ANOVA comparing regressive and non-regressive
autism cases and controls showed a significant difference in the
protein contents among these three groups (F [df=2,15]=9.770,
p=0.002). Post-hoc pairwise comparisons among the groups
revealed a significant decrease in the protein contents of PKA (C-
a) in individuals with regressive autism (mean 6 S.E=0.3460.09)
as compared to control (mean 6 S.E.=0.6460.05, p=0.019,
Bonferroni-adjusted) and individuals with non-regressive autism
(mean 6 S.E.=0.8360.09, p=0.002, Bonferroni-adjusted), sug-
gesting that the protein contents of PKA are affected in regressive
autism. PKA contents were similar between non-regressive autism
and control groups, and when the entire autism group (regressive
and non-regressive) was compared with the control group.
Discussion
ASDs are complex neurodevelopmental disorders. The com-
plexity of ASDs is further increased because some affected
individuals fall in the sub-group of regressive autism [7].
Behavioral changes in regressive autism fall into two broad
domains: (a) loss of vocalization and (b) loss of social skills. The rate
of regressive autism varies from 15% to 62% of cases in different
studies [4–7]. While Lord et al. reported that 29% of the children
they studied who were diagnosed with autism had lost language
skills for meaningful words, and another 9% lost non-word
vocalizations [5], Goldberg et al. reported regression in 62% of
children [4]. Loss of spoken words generally associates with loss of
social behavior [6], but some affected children show only loss of
social skills [4]. We report here that individuals with regressive
autism have decreased PKA activity in the frontal cortex of the
brain. This decreased PKA activity in autistic regression may be
attributed to the decreased protein contents of PKA because the
protein content of PKA (C-a subunit) was also decreased in the
frontal cortex of individuals with regressive autism. Interestingly,
such changes were not observed in other brain regions of
individuals with regressive autism, or in the frontal cortex and
other brain regions of individuals with non-regressive autism.
These results suggest that alterations in PKA activity and PKA
expression are specific to the frontal lobe in regressive autism.
Our results suggest that PMI and age cannot account for the
observed alteration in PKA in regressive autism. Other factors,
such as comorbidity with seizure disorder, reported for three of 10
autism cases (of which two had regressive autism, and one had
non-regressive autism), and medications, reported for two
regressive autism cases, four non-regressive autism cases, and
two control cases, do not seem to be contributing factors to the
altered activity or expression of PKA in regressive autism.
Figure 2. Relative protein levels of PKA (C-a) in the frontal cortex of regressive autism, non-regressive autism, and age-matched
control subjects. Western blot analyses of C-a subunit of PKA in the frontal cortex of individuals with regressive and non-regressive autism, and
age-matched control subjects are represented in Fig. 2A. The relative density of PKA (C-a) normalized with the density of b-actin (loading control) is
shown in Fig. 2B. Data represent mean 6 S.E.
doi:10.1371/journal.pone.0023751.g002
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done to explore this issue.
cAMP is one of the key factors for neuronal outgrowth, plasticity,
and regeneration. Members of the cAMP-dependent second-
messenger pathways participate in the regulation of cellular growth
and differentiation and are also implicated in a variety of embryonic
stages including brain development [24]. The PKA pathway is also
recognized as an essential component in memory formation.
Several studies in Drosophila have demonstrated the role of PKA
in memory formation [25–29]. Mutations in the rutabaga gene,
which encodes adenylate cyclase, caused significant defects in short-
termmemory [25].Reducedexpression oractivityofDC0(the gene
encoding the catalytic subunit of PKA) caused deficits in learning,
short-term memory, and middle-term memory [26–28]. Studies
havealso shown that pharmacological agents such as cAMP analogs
and rolipram (an inhibitor of PDE), which are known to increase
PKA activity, could improve memory [30,31].
G-protein–coupled adenylate cyclase converts ATP to cAMP,
which in turn binds to regulatory subunits of PKA. Following this
event, catalytic subunits of PKA are released, which are the
activated forms of PKA. PKA then phosphorylates and alters the
activity of enzymes and many target proteins such as ion channels,
chromosomal proteins, and transcription factors. cAMP response-
binding protein (CREB) is one of the targets of PKA-mediated
phosphorylation. CREB, upon activation by PKA, binds to certain
DNA sequences (cAMP response elements), thereby stimulating
the transcription of downstream genes and the synthesis of
proteins. The CREB transcription factor is also required for long-
term memory formation [32–34]. It is possible that a decrease in
the activity of PKA in regressive autism may result in reduced
phosphorylation of CREB, and thus reduced transcription and
altered synthesis of some proteins.
Given that PKA is activated by cAMP, and PDE regulates the
levels of cAMP, a discussion on PDE becomes imperative. Altered
levels of PDE4 in the cerebella of autism subjects were reported by
Fatemi and group [23]. Other studies have suggested a role of
PDE4 in learning and memory in behavioral models of mice, rats,
and monkeys [35,36]. PDE4 is also reported to be involved in
behavior sensitivity to antidepressant drugs in animals [37]. PDE
inhibitors such as rolipram could improve object recognition
[38,39], passive avoidance [40,41], radial arm maze [40–42],
Morris water maze [43], and contexual fear conditioning
[30,43,44]. PDE4 has also been studied as a potential therapeutic
target for depressive disorders. It has been suggested that rolipram
may have potential therapeutic benefits for major depression [45],
Alzheimer’s disease [36,46], Parkinson’s disease [47,48], schizo-
phrenia [49,50], and tardive dyskinesia [51,52].
Several reports suggest that some proteins related to the PKA
pathway are involved in autism. Extensive evidence indicates
hyperserotonemia in autism [53–55]. PKA regulates serotonergic
activity in the brain [56]. Galter and Unsicker [57] reported that
co-activation of cAMP- and tyrosine receptor kinase B (TrkB)–
dependent signaling pathways plays an important role in
maintaining the serotonergic neuronal phenotype. TrkB is also
regulated by the cAMP/CREB pathway in neurons [58].
Furthermore, transcriptional activity of the engrailed-2 gene is
also regulated by PKA [59]. The importance of engrailed can be
envisioned because of its crucial roles in brain development [60]
and in the development of autism [61–65].
In conclusion, this study suggests that the frontal cortex may be
the region of the brain involved in regressive autism, where
abnormalities such as decreased activity and expression of PKA
can affect the signal transduction. It may have multiple effects on
signal transduction pathways, which may also influence seroto-
nergic neurons, TrkB, and engrailed-2, all of which have been
suggested to be involved in the development of autism.
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